Oct 29: The Art of the #SBIR/ #STTR Deal: Best Practices in Improving Your Proposal with Olessia Smotrova, CF.APMP Fellow, Richard Bendis, Brittany Sickler, and Brandon Mason (https://expo.tedco.md)
America’s Seed Fund (the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs) annually provides approximately over $3 billion in non-dilutive early-stage technology funding. The SBIR Road Tour is an opportunity for tech innovators, entrepreneurs, and researchers to learn how to access this funding, meet one-on-one with decision makers, and connect with local state innovation ecosystem members. This one-day event will provide attendees, including women and minority entrepreneurs, the opportunity to engage with representatives from various SBIR/STTR agencies.
If you’re an innovator, entrepreneur, researcher, or small technology firm, don’t miss this opportunity!
This year’s QS World University Ranking results have been released, and Johns Hopkins University earned spots as the 12th best in the United States and 24th overall in the world.
Access to capital is often considered primary challenge preventing Maryland from being the top-ranked state for biotech.
The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a biomanufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, Proof of Concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research enterprise between the University of Maryland and the National Institute of Standards and Technology.
Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million Series C financing.
Leading scientists, public policy experts, and biotech industry leaders joined forces today to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance. Working to Fight AMR will also advocate for policies that catalyze the creation of new medicines.
This article is the second in a 4-part series. Part 1 offered background on innovation districts—what they are, where they’re located, how colleges and universities relate, how P3s relate, etc. Part 3 will look at why schools might want to and might not want to consider pursuing an innovation district. Part 4 will feature an interview with Dr. Jane Talkington, scholar of innovation districts for higher ed.
What is the difference between research parks and innovation districts?
Darmody: The terms are somewhat interchangeable, but essentially, innovation districts generally are more urban in nature with mixed-use amenities, whereas traditional research parks grew up around universities and are in rural, suburban, and urban areas, such as Boston and Austin, but also Lincoln, Nebraska, and Champaign, Illinois. When it comes down to it, though, they share a base concept: Schools and other anchor institutions are trying to build space-placed entities, and corporations come to the university for things like talent.
BHI is looking forward to working and partnering with you. We also want to thank his predecessor, Jeff Gallagher, for his 7 years of service. Thank you for your work to help build the BioHealth Capital Region and its efforts to become the Top 3 by 2023.
You can follow along with VirginiaBio at:
The record-high surge of initial public offerings (IPOs) in biopharma last year was especially good news for CEOs of many of those newly public companies.